Wockhardt surges on getting CDSCO nod for exporting up to 100 million doses of Sputnik Vaccines
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Wockhardt is currently trading at Rs. 406.80, up by 18.75 points or 4.83% from its previous closing of Rs. 388.05 on the BSE.
The scrip opened at Rs. 402.25 and has touched a high and low of Rs. 408.10 and Rs. 398.90 respectively. So far 8202 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 804.50 on 26-May-2021 and a 52 week low of Rs. 379.80 on 27-Jan-2022.
Last one week high and low of the scrip stood at Rs. 408.10 and Rs. 386.50 respectively. The current market cap of the company is Rs. 4300.20 crore.
The promoters holding in the company stood at 67.13%, while Institutions and Non-Institutions held 3.04% and 29.83% respectively.
Wockhardt has received permission from the Central Drugs Standard Control Organization (CDSCO) to export up to 80 million doses of Sputnik Light and up to 20 million doses of Sputnik V Component I vaccine.
The company's Bulk vaccine and Fill-Finish manufacturing facilities at Waluj and Shendra, Aurangabad respectively were jointly inspected and approved by Drug inspectors from CDSCO (West zone) & Aurangabad State FDA and Expert from CDL Kasauli to receive export NOC.
Wockhardt’s state-of-the-art automated manufacturing facilities in Aurangabad are dedicated to produce world class high quality injectable products. Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against COVID-19 based on the technology transfer from Gamaleya National Research Institute of Epidemiology and Microbiology.
Wockhardt is a research based global pharmaceutical and Biotech Company headquartered in Mumbai, India.
